Beneficial Effect of Calcium Treatment for Hyperkalemia Is Not Due to "Membrane Stabilization"

Joseph S Piktel1, Xiaoping Wan2, Shalen Kouk3

  • 1Department of Emergency Medicine, Emergency Care and Research and Innovation, MetroHealth Campus, Case Western Reserve University, Cleveland, OH.

Critical Care Medicine
|September 23, 2024
PubMed

Insights

Calcium treatment for hyperkalemia restores cardiac conduction via calcium-dependent pathways, not by stabilizing the membrane potential. This finding explains how calcium effectively treats conduction abnormalities in hyperkalemia.

Area of Science:

  • Cardiovascular Physiology
  • Electrophysiology
  • Medical Research

Background:

  • Hyperkalemia is a critical condition causing dangerous heart rhythm disturbances.
  • Calcium (Ca 2+ ) is used to treat hyperkalemia, but its mechanism is unclear.
  • Current theories suggest calcium stabilizes cell membranes by restoring resting membrane potential (RMP).

Purpose of the Study:

  • To investigate the electrophysiologic effects of hyperkalemia.
  • To elucidate the therapeutic mechanisms of calcium (Ca 2+ ) treatment in hyperkalemia.

Main Methods:

  • Controlled laboratory experiments using canine cardiac myocytes and tissue.
  • Recorded optical action potentials and electrocardiograms during varying potassium levels and Ca 2+ treatment.
  • Measured resting membrane potential (RMP) in isolated myocytes.

Main Results:

  • Hyperkalemia significantly slowed conduction velocity (CV) and shortened action potential duration (APD), causing QRS widening and sine wave patterns.
  • Calcium (Ca 2+ ) treatment improved CV and normalized electrocardiograms but did not restore APD.
  • Calcium (Ca 2+ ) did not restore elevated RMP, suggesting a mechanism beyond membrane stabilization.
  • Calcium's therapeutic effect was reduced by L-type calcium channel blockade.

Conclusions:

  • Calcium (Ca 2+ ) treatment for hyperkalemia facilitates conduction through Ca 2+ -dependent propagation.
  • The mechanism is not related to restoring resting membrane potential (RMP) or "membrane stabilization."
  • Provides a mechanistic basis for using calcium in hyperkalemia-induced conduction abnormalities like QRS prolongation.
Abstract

Related Concept Videos

Antihypertensive Drugs: Potassium-Sparing Diuretics01:28

Antihypertensive Drugs: Potassium-Sparing Diuretics

Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
473
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
791
Antihypertensive Drugs: Action of Calcium Channel Blockers01:18

Antihypertensive Drugs: Action of Calcium Channel Blockers

Calcium ions are essential to contract smooth muscle cells in blood vessels. They enter these cells through voltage-dependent calcium channels, specifically L-type calcium channels in the cell membrane. These L-type calcium channels are integral to the excitation-contraction coupling process in smooth muscle. When a stimulus is received by smooth muscle cells, their membrane depolarizes. This alteration in membrane potential instigates the opening of L-type calcium channels. As a result,...
471
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
924
Antiepileptic Drugs: Calcium Channel Blockers01:17

Antiepileptic Drugs: Calcium Channel Blockers

Calcium channel blockers, a class of antiepileptic drugs, regulate the flow of calcium ions within neurons.
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
341
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
539